Drug-specific hypophosphatemia and hypersensitivity reactions following different intravenous iron infusions

DOI: 10.1111/bcp.13189
British Journal of Clinical Pharmacology, 2017, 83, 1118-1125.

#	Paper	IF	Citations
56	Iron isomaltoside-1000/ferric carboxymaltose. *Reactions Weekly*, **2017**, 1661, 185-185	0	
55	Drug-specific hypophosphatemia and hypersensitivity reactions following different intravenous iron infusions. *British Journal of Clinical Pharmacology*, **2017**, 83, 1118-1125	3.8	49
54	A controlled study of the effects of ferric carboxymaltose on bone and haematinic biomarkers in chronic kidney disease and pregnancy. *Nephrology Dialysis Transplantation*, **2018**, 33, 1628-1635	4.3	19
53	Severe hypophosphataemia after intravenous iron administration. *BMJ Case Reports*, **2017**, 2017,	0.9	16
52	Reply to "Comment on Neiser et al. Assessment of Dextran Antigenicity of Intravenous Iron Preparations with Enzyme-Linked Immunosorbent Assay (ELISA). Int. J. Mol. Sci. 2016, 17, 1185.". *International Journal of Molecular Sciences*, **2017**, 18,	6.3	
51	The NIMO Scandinavian Study: A Prospective Observational Study of Iron Isomaltoside Treatment in Patients with Iron Deficiency. *Gastroenterology Research and Practice*, **2017**, 2017, 4585164	2	17
50	Management of anemia in inflammatory bowel disease: a challenge in everyday clinical practice. *Przeglad Gastroenterologiczny*, **2017**, 12, 239-243	6	9
49	Fast Track Anaemia Clinic (FTAC) and Intravenous Iron Administration: Its Relevance and Application Today in India. *Indian Journal of Hematology and Blood Transfusion*, **2018**, 34, 343-344	0.7	
48	Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: A randomized trial. *American Journal of Hematology*, **2018**, 93, 683-690	7.1	70
47	Pharmacokinetics, pharmacodynamics, safety, and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in Japanese volunteers with iron-deficiency anemia. *International Journal of Hematology*, **2018**, 107, 519-527	2.3	8
46	Ferric Carboxymaltose: A Review in Iron Deficiency. *Drugs*, **2018**, 78, 479-493	12.1	23
45	Hypophosphatemia, Severe Bone Pain, Gait Disturbance, and Fatigue Fractures After Iron Substitution in Inflammatory Bowel Disease: A Case Report. *Journal of Bone and Mineral Research*, **2018**, 33, 534-539	6.3	21
44	The safety of available treatment options for iron-deficiency anemia. *Expert Opinion on Drug Safety*, **2018**, 17, 149-159	4.1	33
43	Intravenous Irons: From Basic Science to Clinical Practice. *Pharmaceuticals*, **2018**, 11,	5.2	29
42	[Intravenous Iron Substitution in Chronic Disease - in Whom, When and How?]. *Deutsche Medizinische Wochenschrift*, **2019**, 144, 969-977	0	
41	Intravenous iron induced severe hypophosphatemia in a gastric bypass patient. *Endocrinología Diabetes Y Nutrición (English Ed)*, **2019**, 66, 340-342	0.1	
40	Reply: On the safety of intravenous iron formulations. *Medicina Clínica*, **2019**, 152, 204-205	1	

39	Reply. *Medicina Clínica*, **2019**, 152, 205-206	1	
38	Intravenous Iron Use in the Care of Patients with Kidney Disease. *Clinical Journal of the American Society of Nephrology: CJASN*, **2019**, 14, 1528-1530	6.9	1
37	Reply. *Medicina Clínica (English Edition)*, **2019**, 152, 205-206	0.3	
36	Authors' reply to Schaffalitzky de Muckadell and colleagues' Comment on "Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron (III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase® between 2014 and 2017". *Drug Safety*, **2019**, 42, 693-696	5.1	2
35	Reply: On the safety of intravenous iron formulations. *Medicina Clínica (English Edition)*, **2019**, 152, 204-205	0.3	
34	Management of iron deficiency. *Hematology American Society of Hematology Education Program*, **2019**, 2019, 315-322	3.1	15
33	Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron (III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase® between 2014 and 2017. *Drug Safety*, **2019**, 42, 463-471	5.1	23
32	Comparison of hypersensitivity reactions of intravenous iron: iron isomaltoside-1000 (Monofer®) versus ferric carboxy-maltose (Ferinject®). A single center, cohort study. *British Journal of Clinical Pharmacology*, **2019**, 85, 385-392	3.8	16
31	Anemia in Chronic Kidney Disease. **2019**, 136-144.e6		1
30	Reported Severe Hypersensitivity Reactions after Intravenous Iron Administration in the European Economic Area (EEA) Before and After Implementation of Risk Minimization Measures. *Drug Safety*, **2020**, 43, 35-43	5.1	23
29	Severe hypophosphataemia following ferric carboxymaltose infusion in paediatric patients with inflammatory bowel disease. *Frontline Gastroenterology*, **2020**, 11, 324-326	2.6	6
28	Drug-Induced Hypophosphatemia: Current Insights. *Drug Safety*, **2020**, 43, 197-210	5.1	13
27	Eisenmangelanämie bei gastrointestinalen Erkrankungen ist multifaktoriell. *Gastro-News*, **2020**, 7, 30-41	0	
26	A Pooled Analysis of Serum Phosphate Measurements and Potential Hypophosphataemia Events in 45 Interventional Trials with Ferric Carboxymaltose. *Journal of Clinical Medicine*, **2020**, 9,	5.1	8
25	Treatment of anemia in cancer patients undergoing chemotherapy with intravenous ferric carboxymaltose without erythropoiesis-stimulating agents. *Therapeutic Advances in Medical Oncology*, **2020**, 12, 1758835920953292	5.4	4
24	Case report: A rare cause of severe hypophosphatemia. *Annales d'Endocrinologie*, **2020**, 81, 125-126	1.7	3
23	Factors influencing safety and efficacy of intravenous iron-carbohydrate nanomedicines: From production to clinical practice. *Nanomedicine: Nanotechnology, Biology, and Medicine*, **2020**, 26, 102178	6	13
22	High Risk of Hypophosphatemia in Patients with Previous Bariatric Surgery Receiving Ferric Carboxymaltose: A Prospective Cohort Study. *Obesity Surgery*, **2020**, 30, 2659-2666	3.7	3

21	Hypophosphatemia Associated with Intravenous Iron Therapies for Iron Deficiency Anemia: A Systematic Literature Review. *Therapeutics and Clinical Risk Management*, **2020**, 16, 245-259	2.9	30
20	An evaluation of ferric derisomaltose as a treatment for anemia. *Expert Review of Hematology*, **2021**, 14, 7-29	2.8	3
19	Effects of Digestive Diseases on Bone Metabolism. **2021**, 1023-1031.e7		0
18	Hypophosphataemia, fibroblast growth factor 23 and third-generation intravenous iron compounds: a narrative review. *Drugs in Context*, **2021**, 10,	5.2	4
17	Parenteral iron therapy and phosphorus homeostasis: A review. *American Journal of Hematology*, **2021**, 96, 606-616	7.1	5
16	Iron replacement therapy in the management of anaemia in non-dialysis chronic renal failure patients: Perspective of the Spanish Nephrology Society Anaemia Group. *Nefrologia*, **2021**, 41, 123-136	1.5	3
15	Refractory hypophosphatemia following ferric carboxymaltose administration. *CEN Case Reports*, **2021**, 10, 473-475	1	1
14	Iron replacement therapy in the management of anaemia in non-dialysis Chronic kidney disease patients: Perspective of the Spanish Nephrology Society Anaemia Group. *Nefrologia*, **2021**, 41, 123-136	0.4	
13	[Hypophosphatemia following the administration of intravenous iron formulations: A case report and literature review]. *Therapie*, **2021**, 76, 705-714	3.8	1
12	Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. *Kidney International*, **2021**, 99, 1280-1295	9.9	18
11	Intravenous iron induced severe hypophophatemia in a gastric bypass patient. *Endocrinologia, Diabetes Y Nutrición*, **2019**, 66, 340-342	1.3	3
10	Severe FGF23-based hypophosphataemic osteomalacia due to ferric carboxymaltose administration. *BMJ Case Reports*, **2018**, 2018,	0.9	30
9	Randomized trial of intravenous iron-induced hypophosphatemia. *JCI Insight*, **2018**, 3,	9.9	80
8	Current misconceptions in diagnosis and management of iron deficiency. *Blood Transfusion*, **2017**, 15, 422-437	3.6	48
7	Efficacy of intra-operative administration of iron isomaltoside for preventing postoperative anaemia after total knee arthroplasty: A randomised controlled trial. *European Journal of Anaesthesiology*, **2021**, 38, 358-365	2.3	2
6	Osteomalacia and Insufficiency Fractures Secondary to Intravenous Iron Therapy: A Case Report. *Journal of Orthopaedic Case Reports*, **2020**, 10, 4-7	0.3	3
5	Safety of Ferric Carboxymaltose in Children: Report of a Case Series from Greece and Review of the Literature.. *Paediatric Drugs*, **2022**, 1	4.2	0
4	Osteomalacia as a complication of intravenous iron infusion: a systematic review of case-reports.. *Journal of Bone and Mineral Research*, **2022**,	6.3	1

3	Hypersensitivity reactions associated with iron isomaltoside and ferric carboxymaltose. **2022**,	0
2	Effect of Intravenous Iron Administration on Bone Mineral and Iron Homeostasis in Patients with Inflammatory Bowel DiseaseResults of a Prospective Single-Centre Study. **2023**, 13, 458	0
1	Adjunctive therapeutic effects of micronutrient supplementation in inflammatory bowel disease. 14,	0